U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07516093) titled 'Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL' on March 31.
Brief Summary: The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
B-cell Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Intervention:
DRUG: NX-5948
Administered orally once daily
DRUG: Pirtobrutinib
Administered orally ...